ARG23874
Goat anti-Human IgG (Fc) antibody (HRP), pre-adsorbed
Goat anti-Human IgG (Fc) 抗体 (HRP), pre-adsorbed for ELISA,Flow cytometry,FLISA,Western blot and Human
参考文献5
概述
| 产品描述 | HRP-conjugated Goat Polyclonal antibody recognizes Human IgG (Fc) |
|---|---|
| 反应物种 | Hu |
| 不反应物种 | Ms, Rat, Bov, Chk, Goat, Gpig, Hm, Hrs, Rb, Sheep |
| 应用 | ELISA, FACS, FLISA, WB |
| 特异性 | Reacts with the Fc region of human IgG. Minimal reaction to Fab region of human IgG and other human immunoglobulins. Minimal cross reactivity with bovine, mouse, horse, rat, goat, sheep, rabbit, hamster, chicken, and guinea pig serum proteins. |
| 宿主 | Goat |
| 克隆 | Polyclonal |
| 同位型 | IgG |
| 靶点名称 | IgG (Fc) |
| 抗原物种 | Human |
| 抗原 | Human IgG |
| 偶联标记 | HRP |
应用说明
| 预吸附 | Human IgG Fab, IgM, and IgA; Rabbit, mouse, rat, bovine, horse, hamster, goat, sheep, chicken, and guinea pig serum proteins. | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 应用建议 |
|
||||||||||
| 应用说明 | * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. |
属性
| 形式 | Liquid |
|---|---|
| 纯化 | Affinity purification with immunogen. |
| 缓冲液 | PBS (pH 7.4) and 50% Glycerol. |
| 稳定剂 | 50% Glycerol |
| 存放说明 | Aliquot and store in the dark at 2-8°C. Keep protected from prolonged exposure to light. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. |
| 注意事项 | For laboratory research only, not for drug, diagnostic or other use. |
生物信息
| 产品亮点 | Related news: Comprehensive anti-Human secondary antibodies |
|---|
检测图片 (1) Click the Picture to Zoom In
-
ARG23874 Goat anti-Human IgG (Fc) antibody (HRP) (pre-adsorbed) ELISA image
ELISA: The plate was coated with purified human IgG Fc and IgG Fab. Immunoglobulins were detected with serially diluted ARG23874 Goat anti-Human IgG (Fc) antibody (HRP) (pre-adsorbed).
文献引用
Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19
ELISA /
Prospective longitudinal analysis of antibody response after standard and booster doses of SARS-COV2 vaccination in patients with early breast cancer
ELISA /
Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection
ELISA /
Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity
ELISA /
Persistent Antibody Responses up to 18 Months after Mild SARS-CoV-2 Infection
ELISA /
